Study of Xenon Treatment to Protect the Brain and Improve Recovery After Aneurysmal Subarachnoid Hemorrhage

What this Trial Is About

Researchers are evaluating the neuroprotective effects of xenon gas in patients who have experienced an aneurysmal subarachnoid hemorrhage aSAH, a type of brain bleed. The study aims to compare brain white matter damage between patients treated with xenon and those receiving standard care. The main goal is to see if xenon can reduce brain injury as measured by advanced MRI imaging within the first 48 to 96 hours after the hemorrhage. Participants will be randomly assigned to one of two groups the control group receiving standard care with airoxygen and normal body temperature, and the xenon group receiving inhaled xenon gas at a concentration of 50% mixed with airoxygen alongside standard care. The xenon treatment will last for 24 hours. Various brain imaging techniques such as CT angiography, MRI, and PET scans will be used to monitor brain injury and recovery over time. Blood and spinal fluid samples will also be collected to study biomarkers related to brain stress and injury. During the study, participants will undergo neurological evaluations at 3, 12, and 24 months after their hemorrhage to assess long-term outcomes. Researchers will also measure brain pressure, cardiac function, and biochemical markers during the initial intensive care period. The study includes a total follow-up of up to 2 years to evaluate the safety and effectiveness of xenon treatment compared to standard care in protecting the brain after aSAH.

Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage